Shafaat Ali Choyon.

Essay · Artificial Intelligence

Where health AI actually lands by 2027: a builder's bet

By Md Shafaat Ali Choyon MPH · CHES® · MBA · MCIM · builds & runs AI in production · Growth & health strategist · 6 min read ·

I build and run AI in production, so instead of another "AI will change everything" prediction, here's a narrower, more useful one: three bets on where health AI actually lands by 2027, each grounded in something I've shipped, not just read.

Health AI in 2027, a builder's bet, 70% of value is people, 95% of pilots stall, two markets with two jobs.
The bet, at a glance, click to enlarge.

Where does health AI actually land by 2027?

The uncomfortable data from the last two years is that most enterprise AI pilots delivered no measurable return, by one MIT figure, around 95% showed zero P&L impact. Not because the models failed, but because the organizations didn't change around them. BCG's research pins roughly 70% of AI's value on people and process, not the technology. I've lived the smaller version of this: the systems I've shipped worked when I redesigned the workflow and trained the people around the tool, and stalled when I didn't. By 2027 the health systems winning with AI will be the ones that funded the unglamorous 70%.

Bet 2: judgment becomes the premium skill

As models get cheaper and more capable, the scarce skill won't be prompting them. It'll be knowing exactly which parts of a clinical or operational job to hand over and which to keep human. In my own production work the highest-leverage decision is never the prompt, it's drawing the line: automate the repetitive 80%, and defend the 20% where a wrong answer is dangerous or erodes trust. That line-drawing is a discipline, and it's learnable, which means it's teachable, which means it's a moat you can build on purpose.

Bet 3: plumbing decides the winners

The flashiest demo still dies if it can't write to the record, fit the workflow, or clear governance. I've lived this on the operations side, digitizing a multi-entity clinical group taught me that the durable wins come from integration and process, not from anything that would demo well. Most of the real work in shipping health AI is exactly that: data, integration, and measurement. By 2027 the durable products won't be the smartest; they'll be the best-plumbed.

In 2027, health AI's edge won't come from a bigger model. It'll come from people, judgment, and plumbing, the parts that don't demo well.

The dual-market footnote

These bets hold in both my markets, with a twist. In the US the race is capability and integration; in places like Bangladesh it's access and language. Different frontiers, but both reward the team that engineers trust and fit in, rather than bolting cleverness on top. Whoever masters the boring layers wins the market that looks hard and, usually, the one that looks easy too.

The short version

In your world, is the bottleneck really the model, or the people, judgment, and plumbing around it?

Frequently asked questions

Why do most enterprise AI pilots fail to deliver returns?

By one MIT figure, around 95% of enterprise AI pilots1 showed zero P&L impact, not because the models failed, but because the organizations didn't change around them. BCG's research pins roughly 70%2 of AI's value on people and process, not the technology itself.

What will be the premium skill in health AI by 2027?

As models get cheaper and more capable, the scarce skill won't be prompting them, it'll be judgment: knowing exactly which parts of a job to hand over and which to keep human. Automating the repetitive 80% while defending the 20% where a wrong answer is dangerous is a learnable, teachable discipline.

Why does "plumbing" decide which health AI products win?

The flashiest demo still dies if it can't write to the record, fit the workflow, or clear governance. Digitizing a multi-entity clinical group showed that durable wins come from integration and process, not from anything that demos well, so by 2027 the durable products won't be the smartest, they'll be the best-plumbed.

Sources

  1. MIT (NANDA initiative). legal.io ↗
  2. Boston Consulting Group (BCG) — the 10-20-70 rule. bcg.com ↗

Md Shafaat Ali Choyon (MPH, CHES®, MBA, MCIM) is a growth, marketing and public-health strategist who builds and runs AI in production, with 17 years across telecom, fintech, e-commerce, consumer tech and healthcare in the US and Bangladesh. See the essays or the portfolio.

Get new essays by email

New pieces on AI in production, growth, and public health — occasional, no spam, unsubscribe anytime.

Same list as HSREP — you’ll get the essays and the occasional research note.